.2023 .. Global tuberculosis report, : .
Lange C. .2019 .Drug-resistant tuberculosis: an update on disease burden, diagnosis and treatment. , 394(10202) : 953-966.
Dheda K. .2017 .The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrugresistant, extensively drug-resistant, and incurable tuberculosis. The Lancet Respiratory Medicine vol. 5 no. 4, : 291-360.
Telenti A. .1993 .Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. , 341(8846) : 647-650.
Deun Van,A. Van .2009 .Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. ” Journal of Clinical, 47(11) : 3501-3506.
Zhang Y.,Yew Y. .2015 .Mechanisms of drug resistance in Mycobacterium tuberculosis. International Journal of Tuberculosis and Lung, 19(11) : 1276-1289.
Ramaswamy S.,Musser J.M. “ . .Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis. ” Tuberculosis and Lung, 79(1) : 3-29.
Somoskoví A. . .Diagnostic implications of Mycobacterium tuberculosis complex line probe assays. ” Clinical Microbiology Reviews, 26(3) : 421-439.
Cambau E. .2016 .Revisiting susceptibility testing in MDRTB.” Clinical Microbiology and. , 22(11) : 971-980.
Sandgren A. .2009 .Tuberculosis drug resistance mutation database. PLoS Medicine vol. 6 no. 2, : e1000002.
.2016 .The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin. , : .
Lawn S.D.,Zumla A.I. .2011 .. , 378(9785) : 57-72.
Fox G.J. .2017 .Preventing the spread of multidrug-resistant tuberculosis in children.” The Lancet Infectious Diseases vol. , 17(12) : e293-e302.
Dean A.S. .2014 .Epidemiology of drug-resistant tuberculosis. International Journal of Tuberculosis and Lung, 18(12) : 1436-1442.
Cegielski J.P. . .Extensively drug-resistant tuberculosis. ” Clinical Infectious Diseases, 59(5) : 728-735.
Nathavitharana R.R. . .Accuracy of molecular diagnostics for TB.” Clinics in Chest Medicine vol. , 40(4) : 703-719.
Lifescience GmbH. “GenoType MTBDRplus VER Hain .2016 .2.0: instructions for use. , : .
Lifescience GmbH. “GenoType MTBDRsl VER Hain .2016 .2.0: instructions for use. , : .
Altman D.G .1991 .. , : .
Rosner B. .2015 .Fundamentals of Biostatistics. , : .
“ . .. ” MSD Manual Professional Edition., : .
Mohanty P.S. . .Host factors in leprosy epidemiology: high leprosy among children and adults aged 20-30 years in endemic regions. , : .
de Oliveira A.L. . .Leprosy among children under 15 years of age: literature review; children aged 10-14 years show active disease and ongoing transmission. , : .
Mahajan N. . .Evidence for Mycobacterium leprae drug resistance in a large cohort of leprous neuropathy patients from India. American Journal of Tropical Medicine and Hygiene, 102(3) : 547-552.
Pereira A.L. . .Leprosy: clinical and epidemiological study in patients above 60 years in Espírito Santo State, Brazil; most cases between 61-80 years, with male predominance and multibacillary forms. , : .
. .Age related rate of antimicrobial resistance in clinical isolates. ” BMC, 23 : .
Zignol M. .2018 .Surveillance of anti-tuberculosis drug resistance. ” Emerging Infectious, 24(12) : 230-238.
Central TB,Division. “National Tuberculosis Elimination TB .2023 .Programme (NTEP) guidelines. Ministry of Health and Family Welfare, : .